Meeting
2014 ASCO Annual Meeting
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
Authors
Scott Joseph Antonia
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Scott Joseph Antonia , Scott N. Gettinger , Laura Quan Man Chow , Rosalyn A. Juergens , Hossein Borghaei , Yun Shen , Christopher Harbison , Allen C. Chen , Neal Ready , Naiyer A. Rizvi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01454102
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8023)
DOI
10.1200/jco.2014.32.15_suppl.8023
Abstract #
8023
Poster Bd #
37
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
First Author: Julie R. Brahmer
Poster
2021 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
First Author: Luis G. Paz-Ares
Poster
2020 ASCO Virtual Scientific Program
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2018 ASCO Annual Meeting
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon